5/16
06:21 am
bbio
BridgeBio Pharma, Inc. (NASDAQ: BBIO) was upgraded by analysts at Evercore ISI to a "strong-buy" rating.
Medium
Report
BridgeBio Pharma, Inc. (NASDAQ: BBIO) was upgraded by analysts at Evercore ISI to a "strong-buy" rating.
5/15
07:30 am
bbio
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
5/14
08:07 am
bbio
BridgeBio Pharma, Inc. (NASDAQ: BBIO) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $50.00 price target on the stock.
Low
Report
BridgeBio Pharma, Inc. (NASDAQ: BBIO) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $50.00 price target on the stock.
5/14
07:42 am
bbio
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024 [Yahoo! Finance]
Low
Report
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024 [Yahoo! Finance]
5/14
07:30 am
bbio
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024
Low
Report
BridgeBio Pharma to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2024
5/13
07:46 am
bbio
BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensit
Medium
Report
BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensit
5/13
07:30 am
bbio
BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensit
Medium
Report
BridgeBio Pharma Presents Additional Data and Analyses from its Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at ESC-HF, Including That Acoramidis Treatment Significantly Reduced All-Cause Mortality in a Pre-specified Sensit
5/4
09:45 am
bbio
What You Need To Know About The BridgeBio Pharma, Inc. (NASDAQ:BBIO) Analyst Downgrade Today [Yahoo! Finance]
Low
Report
What You Need To Know About The BridgeBio Pharma, Inc. (NASDAQ:BBIO) Analyst Downgrade Today [Yahoo! Finance]
5/3
07:00 am
bbio
BridgeBio Pharma First Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
Low
Report
BridgeBio Pharma First Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
5/2
07:30 am
bbio
BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update
Low
Report
BridgeBio Pharma Reports First Quarter 2024 Financial Results and Business Update
5/2
07:13 am
bbio
BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline [Yahoo! Finance]
Low
Report
BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline [Yahoo! Finance]
5/2
07:00 am
bbio
BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline
Low
Report
BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline
4/16
09:15 am
bbio
Sentynl Therapeutics Receives MHRA Authorization of NULIBRY® (fosdenopterin) for Treatment of MoCD Type A in Great Britain [Yahoo! Finance]
Medium
Report
Sentynl Therapeutics Receives MHRA Authorization of NULIBRY® (fosdenopterin) for Treatment of MoCD Type A in Great Britain [Yahoo! Finance]
4/10
07:30 am
bbio
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
4/7
01:25 pm
bbio
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) [Yahoo! Finance]
Neutral
Report
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) [Yahoo! Finance]
4/7
01:15 pm
bbio
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Neutral
Report
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
3/27
08:13 am
bbio
Noetik Appoints Dr. Shafique Virani as Chief Business Officer [Yahoo! Finance]
Low
Report
Noetik Appoints Dr. Shafique Virani as Chief Business Officer [Yahoo! Finance]
3/21
08:00 am
bbio
BridgeBio Pharma, Inc. (NASDAQ: BBIO) is now covered by analysts at Raymond James. They set an "outperform" rating and a $45.00 price target on the stock.
Low
Report
BridgeBio Pharma, Inc. (NASDAQ: BBIO) is now covered by analysts at Raymond James. They set an "outperform" rating and a $45.00 price target on the stock.
3/20
08:08 am
bbio
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its price target raised by analysts at JPMorgan Chase & Co. from $35.00 to $45.00. They now have an "overweight" rating on the stock.
Low
Report
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its price target raised by analysts at JPMorgan Chase & Co. from $35.00 to $45.00. They now have an "overweight" rating on the stock.
3/20
07:30 am
bbio
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
3/19
08:36 am
bbio
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its price target raised by analysts at Cantor Fitzgerald from $60.00 to $70.00. They now have an "overweight" rating on the stock.
Low
Report
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its price target raised by analysts at Cantor Fitzgerald from $60.00 to $70.00. They now have an "overweight" rating on the stock.
3/5
11:53 pm
bbio
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
Low
Report
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
3/5
08:13 am
bbio
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its price target lowered by analysts at Mizuho from $60.00 to $53.00. They now have a "buy" rating on the stock.
Medium
Report
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its price target lowered by analysts at Mizuho from $60.00 to $53.00. They now have a "buy" rating on the stock.
3/4
04:17 pm
bbio
BridgeBio Pharma Announces Proposed Public Offering of Common Stock
Medium
Report
BridgeBio Pharma Announces Proposed Public Offering of Common Stock
3/4
08:06 am
bbio
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $47.00 price target on the stock.
Medium
Report
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $47.00 price target on the stock.